Global Fingolimod Market

Fingolimod Comprehensive Study by Application (Medical Field, Science Research Field, Other Field), Administration (Oral, Injection), Distribution Channel (Healthcare Providers, Online Pharmacies, Medical Clinics, Others) Players and Region - Global Market Outlook to 2030

Fingolimod Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Fingolimod
Fingolimod is used to prevent episodes of symptoms and slow the worsening of disability in adults and children 10 years of age and older with relapsing-remitting forms of multiple sclerosis. Fingolimod is in a class of medications called sphingosine l-phosphate receptor modulators. It works by decreasing the action of immune cells that may cause nerve damage.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Growing focus on drug discovery, speed up delivery of new treatments for patients, the introduction of highly efficient therapies, a multiplicity of new drugs entering the market, huge R&D activities & investments are key factors contributing to Growth of Fingolimod during the forecast period. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Fingolimod market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis(Switzerland), Teva (Israel), Biogen(United States), Genzyme (Sanofi), GlaxoSmithKline(United Kingdom), Merck Serono(Germany), Pfizer (United States), Abbvie (United States) and Acorda Therapeutics(United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Fingolimod market by , Application (Medical Field, Science Research Field and Other Field) and Region.



On the basis of geography, the market of Fingolimod has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Administration, the sub-segment i.e. Oral will boost the Fingolimod market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Healthcare Providers will boost the Fingolimod market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Rising Awareness Among The People, Development In The Drugs And Therapeutics Sector and The Growing Number Of Worsening of Disability

Challenges:
Key Competition R&D for new Solutions in between Key Players

Restraints:
Side Effects of the Fingolimod such as Slow Heartbeat, Rash, Hives, Itching, etc

Opportunities:
Increasing Investments In The Healthcare Sector And involvement Of Government And Support Is Offering The Huge Opportunities Of Growth In The Market

Market Leaders and their expansionary development strategies
In October 2022, Glenmark Pharmaceuticals Inc., USA it has launched their Fingolimod Capsules, 0.5 mg, the generic version of Gilenya®1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.
In February 2023, Cycle Pharmaceuticals Ltd (Cycle) has launched of TASCENSO ODT, its first product to treat MS patients in the US. The launch ensures MS patients in the US currently benefitting from Gilenya, or generic fingolimod, can access appropriate patient support services alongside the bioequivalent, non-generic, TASCENSO ODT.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Medical Field
  • Science Research Field
  • Other Field
By Administration
  • Oral
  • Injection

By Distribution Channel
  • Healthcare Providers
  • Online Pharmacies
  • Medical Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness Among The People, Development In The Drugs And Therapeutics Sector
      • 3.2.2. The Growing Number Of Worsening of Disability
    • 3.3. Market Challenges
      • 3.3.1. Key Competition R&D for new Solutions in between Key Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Fingolimod, by Application, Administration, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Fingolimod (Value)
      • 5.2.1. Global Fingolimod by: Application (Value)
        • 5.2.1.1. Medical Field
        • 5.2.1.2. Science Research Field
        • 5.2.1.3. Other Field
      • 5.2.2. Global Fingolimod by: Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Injection
      • 5.2.3. Global Fingolimod by: Distribution Channel (Value)
        • 5.2.3.1. Healthcare Providers
        • 5.2.3.2. Online Pharmacies
        • 5.2.3.3. Medical Clinics
        • 5.2.3.4. Others
      • 5.2.4. Global Fingolimod Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Fingolimod: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis(Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Teva (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biogen(United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Genzyme (Sanofi)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline(United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck Serono(Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbvie (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Acorda Therapeutics(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Fingolimod Sale, by Application, Administration, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Fingolimod (Value)
      • 7.2.1. Global Fingolimod by: Application (Value)
        • 7.2.1.1. Medical Field
        • 7.2.1.2. Science Research Field
        • 7.2.1.3. Other Field
      • 7.2.2. Global Fingolimod by: Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Injection
      • 7.2.3. Global Fingolimod by: Distribution Channel (Value)
        • 7.2.3.1. Healthcare Providers
        • 7.2.3.2. Online Pharmacies
        • 7.2.3.3. Medical Clinics
        • 7.2.3.4. Others
      • 7.2.4. Global Fingolimod Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Fingolimod: by Application(USD Million)
  • Table 2. Fingolimod Medical Field , by Region USD Million (2018-2023)
  • Table 3. Fingolimod Science Research Field , by Region USD Million (2018-2023)
  • Table 4. Fingolimod Other Field , by Region USD Million (2018-2023)
  • Table 5. Fingolimod: by Administration(USD Million)
  • Table 6. Fingolimod Oral , by Region USD Million (2018-2023)
  • Table 7. Fingolimod Injection , by Region USD Million (2018-2023)
  • Table 8. Fingolimod: by Distribution Channel(USD Million)
  • Table 9. Fingolimod Healthcare Providers , by Region USD Million (2018-2023)
  • Table 10. Fingolimod Online Pharmacies , by Region USD Million (2018-2023)
  • Table 11. Fingolimod Medical Clinics , by Region USD Million (2018-2023)
  • Table 12. Fingolimod Others , by Region USD Million (2018-2023)
  • Table 13. South America Fingolimod, by Country USD Million (2018-2023)
  • Table 14. South America Fingolimod, by Application USD Million (2018-2023)
  • Table 15. South America Fingolimod, by Administration USD Million (2018-2023)
  • Table 16. South America Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 17. Brazil Fingolimod, by Application USD Million (2018-2023)
  • Table 18. Brazil Fingolimod, by Administration USD Million (2018-2023)
  • Table 19. Brazil Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 20. Argentina Fingolimod, by Application USD Million (2018-2023)
  • Table 21. Argentina Fingolimod, by Administration USD Million (2018-2023)
  • Table 22. Argentina Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 23. Rest of South America Fingolimod, by Application USD Million (2018-2023)
  • Table 24. Rest of South America Fingolimod, by Administration USD Million (2018-2023)
  • Table 25. Rest of South America Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 26. Asia Pacific Fingolimod, by Country USD Million (2018-2023)
  • Table 27. Asia Pacific Fingolimod, by Application USD Million (2018-2023)
  • Table 28. Asia Pacific Fingolimod, by Administration USD Million (2018-2023)
  • Table 29. Asia Pacific Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 30. China Fingolimod, by Application USD Million (2018-2023)
  • Table 31. China Fingolimod, by Administration USD Million (2018-2023)
  • Table 32. China Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 33. Japan Fingolimod, by Application USD Million (2018-2023)
  • Table 34. Japan Fingolimod, by Administration USD Million (2018-2023)
  • Table 35. Japan Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 36. India Fingolimod, by Application USD Million (2018-2023)
  • Table 37. India Fingolimod, by Administration USD Million (2018-2023)
  • Table 38. India Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 39. South Korea Fingolimod, by Application USD Million (2018-2023)
  • Table 40. South Korea Fingolimod, by Administration USD Million (2018-2023)
  • Table 41. South Korea Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 42. Taiwan Fingolimod, by Application USD Million (2018-2023)
  • Table 43. Taiwan Fingolimod, by Administration USD Million (2018-2023)
  • Table 44. Taiwan Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 45. Australia Fingolimod, by Application USD Million (2018-2023)
  • Table 46. Australia Fingolimod, by Administration USD Million (2018-2023)
  • Table 47. Australia Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Fingolimod, by Application USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Fingolimod, by Administration USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 51. Europe Fingolimod, by Country USD Million (2018-2023)
  • Table 52. Europe Fingolimod, by Application USD Million (2018-2023)
  • Table 53. Europe Fingolimod, by Administration USD Million (2018-2023)
  • Table 54. Europe Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 55. Germany Fingolimod, by Application USD Million (2018-2023)
  • Table 56. Germany Fingolimod, by Administration USD Million (2018-2023)
  • Table 57. Germany Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 58. France Fingolimod, by Application USD Million (2018-2023)
  • Table 59. France Fingolimod, by Administration USD Million (2018-2023)
  • Table 60. France Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 61. Italy Fingolimod, by Application USD Million (2018-2023)
  • Table 62. Italy Fingolimod, by Administration USD Million (2018-2023)
  • Table 63. Italy Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 64. United Kingdom Fingolimod, by Application USD Million (2018-2023)
  • Table 65. United Kingdom Fingolimod, by Administration USD Million (2018-2023)
  • Table 66. United Kingdom Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 67. Netherlands Fingolimod, by Application USD Million (2018-2023)
  • Table 68. Netherlands Fingolimod, by Administration USD Million (2018-2023)
  • Table 69. Netherlands Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 70. Rest of Europe Fingolimod, by Application USD Million (2018-2023)
  • Table 71. Rest of Europe Fingolimod, by Administration USD Million (2018-2023)
  • Table 72. Rest of Europe Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 73. MEA Fingolimod, by Country USD Million (2018-2023)
  • Table 74. MEA Fingolimod, by Application USD Million (2018-2023)
  • Table 75. MEA Fingolimod, by Administration USD Million (2018-2023)
  • Table 76. MEA Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 77. Middle East Fingolimod, by Application USD Million (2018-2023)
  • Table 78. Middle East Fingolimod, by Administration USD Million (2018-2023)
  • Table 79. Middle East Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 80. Africa Fingolimod, by Application USD Million (2018-2023)
  • Table 81. Africa Fingolimod, by Administration USD Million (2018-2023)
  • Table 82. Africa Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 83. North America Fingolimod, by Country USD Million (2018-2023)
  • Table 84. North America Fingolimod, by Application USD Million (2018-2023)
  • Table 85. North America Fingolimod, by Administration USD Million (2018-2023)
  • Table 86. North America Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 87. United States Fingolimod, by Application USD Million (2018-2023)
  • Table 88. United States Fingolimod, by Administration USD Million (2018-2023)
  • Table 89. United States Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 90. Canada Fingolimod, by Application USD Million (2018-2023)
  • Table 91. Canada Fingolimod, by Administration USD Million (2018-2023)
  • Table 92. Canada Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 93. Mexico Fingolimod, by Application USD Million (2018-2023)
  • Table 94. Mexico Fingolimod, by Administration USD Million (2018-2023)
  • Table 95. Mexico Fingolimod, by Distribution Channel USD Million (2018-2023)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Fingolimod: by Application(USD Million)
  • Table 106. Fingolimod Medical Field , by Region USD Million (2025-2030)
  • Table 107. Fingolimod Science Research Field , by Region USD Million (2025-2030)
  • Table 108. Fingolimod Other Field , by Region USD Million (2025-2030)
  • Table 109. Fingolimod: by Administration(USD Million)
  • Table 110. Fingolimod Oral , by Region USD Million (2025-2030)
  • Table 111. Fingolimod Injection , by Region USD Million (2025-2030)
  • Table 112. Fingolimod: by Distribution Channel(USD Million)
  • Table 113. Fingolimod Healthcare Providers , by Region USD Million (2025-2030)
  • Table 114. Fingolimod Online Pharmacies , by Region USD Million (2025-2030)
  • Table 115. Fingolimod Medical Clinics , by Region USD Million (2025-2030)
  • Table 116. Fingolimod Others , by Region USD Million (2025-2030)
  • Table 117. South America Fingolimod, by Country USD Million (2025-2030)
  • Table 118. South America Fingolimod, by Application USD Million (2025-2030)
  • Table 119. South America Fingolimod, by Administration USD Million (2025-2030)
  • Table 120. South America Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 121. Brazil Fingolimod, by Application USD Million (2025-2030)
  • Table 122. Brazil Fingolimod, by Administration USD Million (2025-2030)
  • Table 123. Brazil Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 124. Argentina Fingolimod, by Application USD Million (2025-2030)
  • Table 125. Argentina Fingolimod, by Administration USD Million (2025-2030)
  • Table 126. Argentina Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 127. Rest of South America Fingolimod, by Application USD Million (2025-2030)
  • Table 128. Rest of South America Fingolimod, by Administration USD Million (2025-2030)
  • Table 129. Rest of South America Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 130. Asia Pacific Fingolimod, by Country USD Million (2025-2030)
  • Table 131. Asia Pacific Fingolimod, by Application USD Million (2025-2030)
  • Table 132. Asia Pacific Fingolimod, by Administration USD Million (2025-2030)
  • Table 133. Asia Pacific Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 134. China Fingolimod, by Application USD Million (2025-2030)
  • Table 135. China Fingolimod, by Administration USD Million (2025-2030)
  • Table 136. China Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 137. Japan Fingolimod, by Application USD Million (2025-2030)
  • Table 138. Japan Fingolimod, by Administration USD Million (2025-2030)
  • Table 139. Japan Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 140. India Fingolimod, by Application USD Million (2025-2030)
  • Table 141. India Fingolimod, by Administration USD Million (2025-2030)
  • Table 142. India Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 143. South Korea Fingolimod, by Application USD Million (2025-2030)
  • Table 144. South Korea Fingolimod, by Administration USD Million (2025-2030)
  • Table 145. South Korea Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 146. Taiwan Fingolimod, by Application USD Million (2025-2030)
  • Table 147. Taiwan Fingolimod, by Administration USD Million (2025-2030)
  • Table 148. Taiwan Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 149. Australia Fingolimod, by Application USD Million (2025-2030)
  • Table 150. Australia Fingolimod, by Administration USD Million (2025-2030)
  • Table 151. Australia Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 152. Rest of Asia-Pacific Fingolimod, by Application USD Million (2025-2030)
  • Table 153. Rest of Asia-Pacific Fingolimod, by Administration USD Million (2025-2030)
  • Table 154. Rest of Asia-Pacific Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 155. Europe Fingolimod, by Country USD Million (2025-2030)
  • Table 156. Europe Fingolimod, by Application USD Million (2025-2030)
  • Table 157. Europe Fingolimod, by Administration USD Million (2025-2030)
  • Table 158. Europe Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 159. Germany Fingolimod, by Application USD Million (2025-2030)
  • Table 160. Germany Fingolimod, by Administration USD Million (2025-2030)
  • Table 161. Germany Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 162. France Fingolimod, by Application USD Million (2025-2030)
  • Table 163. France Fingolimod, by Administration USD Million (2025-2030)
  • Table 164. France Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 165. Italy Fingolimod, by Application USD Million (2025-2030)
  • Table 166. Italy Fingolimod, by Administration USD Million (2025-2030)
  • Table 167. Italy Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 168. United Kingdom Fingolimod, by Application USD Million (2025-2030)
  • Table 169. United Kingdom Fingolimod, by Administration USD Million (2025-2030)
  • Table 170. United Kingdom Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 171. Netherlands Fingolimod, by Application USD Million (2025-2030)
  • Table 172. Netherlands Fingolimod, by Administration USD Million (2025-2030)
  • Table 173. Netherlands Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 174. Rest of Europe Fingolimod, by Application USD Million (2025-2030)
  • Table 175. Rest of Europe Fingolimod, by Administration USD Million (2025-2030)
  • Table 176. Rest of Europe Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 177. MEA Fingolimod, by Country USD Million (2025-2030)
  • Table 178. MEA Fingolimod, by Application USD Million (2025-2030)
  • Table 179. MEA Fingolimod, by Administration USD Million (2025-2030)
  • Table 180. MEA Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 181. Middle East Fingolimod, by Application USD Million (2025-2030)
  • Table 182. Middle East Fingolimod, by Administration USD Million (2025-2030)
  • Table 183. Middle East Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 184. Africa Fingolimod, by Application USD Million (2025-2030)
  • Table 185. Africa Fingolimod, by Administration USD Million (2025-2030)
  • Table 186. Africa Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 187. North America Fingolimod, by Country USD Million (2025-2030)
  • Table 188. North America Fingolimod, by Application USD Million (2025-2030)
  • Table 189. North America Fingolimod, by Administration USD Million (2025-2030)
  • Table 190. North America Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 191. United States Fingolimod, by Application USD Million (2025-2030)
  • Table 192. United States Fingolimod, by Administration USD Million (2025-2030)
  • Table 193. United States Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 194. Canada Fingolimod, by Application USD Million (2025-2030)
  • Table 195. Canada Fingolimod, by Administration USD Million (2025-2030)
  • Table 196. Canada Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 197. Mexico Fingolimod, by Application USD Million (2025-2030)
  • Table 198. Mexico Fingolimod, by Administration USD Million (2025-2030)
  • Table 199. Mexico Fingolimod, by Distribution Channel USD Million (2025-2030)
  • Table 200. Research Programs/Design for This Report
  • Table 201. Key Data Information from Secondary Sources
  • Table 202. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Fingolimod: by Application USD Million (2018-2023)
  • Figure 5. Global Fingolimod: by Administration USD Million (2018-2023)
  • Figure 6. Global Fingolimod: by Distribution Channel USD Million (2018-2023)
  • Figure 7. South America Fingolimod Share (%), by Country
  • Figure 8. Asia Pacific Fingolimod Share (%), by Country
  • Figure 9. Europe Fingolimod Share (%), by Country
  • Figure 10. MEA Fingolimod Share (%), by Country
  • Figure 11. North America Fingolimod Share (%), by Country
  • Figure 12. Global Fingolimod share by Players 2023 (%)
  • Figure 13. Global Fingolimod share by Players (Top 3) 2023(%)
  • Figure 14. Global Fingolimod share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Novartis(Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Novartis(Switzerland) Revenue: by Geography 2023
  • Figure 18. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 19. Teva (Israel) Revenue: by Geography 2023
  • Figure 20. Biogen(United States) Revenue, Net Income and Gross profit
  • Figure 21. Biogen(United States) Revenue: by Geography 2023
  • Figure 22. Genzyme (Sanofi) Revenue, Net Income and Gross profit
  • Figure 23. Genzyme (Sanofi) Revenue: by Geography 2023
  • Figure 24. GlaxoSmithKline(United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline(United Kingdom) Revenue: by Geography 2023
  • Figure 26. Merck Serono(Germany) Revenue, Net Income and Gross profit
  • Figure 27. Merck Serono(Germany) Revenue: by Geography 2023
  • Figure 28. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer (United States) Revenue: by Geography 2023
  • Figure 30. Abbvie (United States) Revenue, Net Income and Gross profit
  • Figure 31. Abbvie (United States) Revenue: by Geography 2023
  • Figure 32. Acorda Therapeutics(United States) Revenue, Net Income and Gross profit
  • Figure 33. Acorda Therapeutics(United States) Revenue: by Geography 2023
  • Figure 34. Global Fingolimod: by Application USD Million (2025-2030)
  • Figure 35. Global Fingolimod: by Administration USD Million (2025-2030)
  • Figure 36. Global Fingolimod: by Distribution Channel USD Million (2025-2030)
  • Figure 37. South America Fingolimod Share (%), by Country
  • Figure 38. Asia Pacific Fingolimod Share (%), by Country
  • Figure 39. Europe Fingolimod Share (%), by Country
  • Figure 40. MEA Fingolimod Share (%), by Country
  • Figure 41. North America Fingolimod Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis(Switzerland)
  • Teva (Israel)
  • Biogen(United States)
  • Genzyme (Sanofi)
  • GlaxoSmithKline(United Kingdom)
  • Merck Serono(Germany)
  • Pfizer (United States)
  • Abbvie (United States)
  • Acorda Therapeutics(United States)
Select User Access Type

Key Highlights of Report


Feb 2024 204 Pages 97 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Fingolimod Market Quantitative research analysis
Global Fingolimod Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis(Switzerland), Teva (Israel), Biogen(United States), Genzyme (Sanofi), GlaxoSmithKline(United Kingdom), Merck Serono(Germany), Pfizer (United States), Abbvie (United States) and Acorda Therapeutics(United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Fingolimod Market during projected period 2023-2030.
The Fingolimod market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Fingolimod Market Report?

Have a Query? Click Here

Other Related Reports

Cannabinoid Drugs Comprehensive Study by Type (Phytocannabinoids, Endocannabinoids, Synthetics), Application (Chronic Diseases, Anxiety, Nausea, Others), End-users (Hospitals, Clinics, Ambulatory Sur...
$ 3650
Epileptic Seizures Treatment Comprehensive Study by Type (Convulsive Status Epilepticus, Non-Convulsive Status Epilepticus), Therapeutic (Midazolam, Alprazolam, Diazepam, Phenytoin, Fosphenytoin, Ot...
$ 3650
Erythropoiesis Stimulating Agents Comprehensive Study by Type (Epoetin Alfa, Epoetin Beta, Epoetin Omega, Epoetin Delta, Darbepoetin Alfa), Application (Cancer, Renal Disorders, Anti-retroviral Treat...
$ 3650
Chemotherapy Drugs Comprehensive Study by Type (Alkylating Agents, Antitumor Antibiotics, Plant Alkaloids, Antimetabolites, Topoisomerase Inhibitors, Miscellaneous Antineoplastic), Route of Administr...
$ 3750
Neurofibromatosis Treatment Drugs Comprehensive Study by Type (Selumetinib, Bevacizumab, Koselugo), Application (Clinic, Hospital, Home Care), Distribution Channel (Online, Offline), Neurofibromas (C...
$ 3350
CBD Oil Extract Comprehensive Study by Application (Medical, Personal Use, Pharmaceutical, Wellness), Source (Hemp, Marijuana) Players and Region - Global Market Outlook to 2026
$ 3500